SCHEDULE: Perceptive Advisors Discloses 8.2% Stake in Amylyx Pharma

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a passive beneficial ownership of 8.2% in Amylyx Pharmaceuticals, Inc.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Amylyx Pharmaceuticals, Inc.
• The Reporting Persons collectively beneficially own 8,952,365 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
• This ownership represents 8.2% of the outstanding Common Stock, calculated based on 109,819,569 shares outstanding as of October 27, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds the shares, with Perceptive Advisors LLC serving as its investment manager and Joseph Edelman as the managing member of Perceptive Advisors.
• The filing certifies that the securities were acquired and are held for investment purposes and not with the intent to change or influence control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a substantial passive stake by Perceptive Advisors, a prominent life sciences investor, can be interpreted as a vote of confidence in Amylyx Pharmaceuticals' current trajectory and management, generally signaling a positive sentiment.

Positives

• A significant stake (8.2%) held by a reputable life sciences investment firm like Perceptive Advisors may signal confidence in Amylyx Pharmaceuticals' long-term prospects.
• The passive nature of the investment, indicated by the Schedule 13G filing, suggests a belief in the company's current management and strategic direction without seeking active control.

Negatives

• No specific negative information regarding Amylyx Pharmaceuticals, Inc. is contained within this beneficial ownership disclosure.

Risks

• No specific risks related to Amylyx Pharmaceuticals, Inc. are detailed in this Schedule 13G filing, as it primarily concerns beneficial ownership disclosure by the Reporting Persons.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Amylyx Pharmaceuticals, Inc.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

The filing indicates continued institutional interest in Amylyx Pharmaceuticals, a company operating in the biotechnology and pharmaceutical sector. Perceptive Advisors is a well-known investor in the life sciences space, and their significant stake suggests a positive view on the company's position within its industry.

Comparison to Industry Standards

• Perceptive Advisors is a prominent investment firm specializing in the life sciences sector. Their investment in Amylyx Pharmaceuticals, Inc. aligns with their strategy of taking significant positions in promising biotechnology companies.
• While specific comparable companies or projects are not mentioned in the filing, Perceptive's track record includes investments in numerous successful biotech firms, suggesting this stake is consistent with their typical investment profile in the industry.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive signal, potentially increasing confidence in the stock.
• Management: The passive nature of the investment suggests support for current management and strategy, reducing immediate pressure for operational changes.

Next Steps

• The Reporting Persons will continue to monitor their investment in Amylyx Pharmaceuticals, Inc.
• Future amendments to this Schedule 13G will be filed if there are material changes to their beneficial ownership or investment intent.

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment by a reputable firm, which is generally a positive signal. However, a Schedule 13G filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing or recently established position. Investors should 'hold' and consider this information as part of a broader due diligence process, looking for further operational updates from Amylyx Pharmaceuticals.

Keywords

Amylyx Pharmaceuticals, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals, Investment, Institutional Investor